Breaking the Chain: The Crucial Role of Prediabetes Screening in Preventing Diabetes and Its Complications Dr. Kaushik Biswas15 May 2024 10:41 AM ISTPreventing Diabetes -A Stitch in Time Saves Nine:Diabetes prevention has become extremely critical, necessitating all healthcare stakeholders'...
Prediabetes Needs Proactive Management In India: Why? Dr Manoj Khandelwal18 April 2024 11:00 AM IST Prediabetes, also termed intermediate hyperglycemia or non-diabetic hyperglycemia, a high-risk state for developing diabetes, is defined by...
EVERGREEN Webinar: Clinical FAQs on T2DM Care, Addressed by Dr V Mohan Dr Jeegar Dattani6 March 2024 12:29 PM ISTThe Evergreen webinar addressed the clinical applicability of Linagliptin and Dapagliflozin in real-world clinical scenarios of type 2 diabetes....
Top 10 Messages from Evergreen Webinar on Clinical Applicability of Linagliptin Dapagliflozin in Type 2 Diabetes, Addressed by Dr V Mohan Dr Jeegar Dattani12 Feb 2024 12:15 PM ISTDr. V. Mohan, M.D., FRCP (London, Edinburgh, Glasgow & Ireland), Ph.D., D.Sc. D.Sc (Hon. Causa), FNASc, FASc, FNA, FACE, FACP, FTWAS, MACP, FRSE....
2023 In Review: Major Developments In The Field Of Endocrinology Dr Akhil Krishna26 Dec 2023 11:15 AM IST Let us take a glimpse into the notable progress and accomplishments within the field of endocrinology for the year 2023. This overview showcases...
Standards of Care in Diabetes 2024: ADA recommends more personalization, additional obesity measurements beyond BMI Medha Baranwal20 Dec 2023 10:00 AM ISTUSA: The American Diabetes Association (ADA) has released new screening and obesity management recommendations for diabetes patients. The updated...
Linagliptin and Dapagliflozin: Therapeutic Applicability in T2DM with High CV Risk Dr. Kamal Kant Kohli13 Dec 2023 11:48 AM ISTType 2 Diabetes Mellitus and Cardiovascular DiseaseType 2 diabetes mellitus (T2DM) prevalence has been increasing globally, particularly in India (1)...
Linagliptin and Dapagliflozin: Evidence for Robust Glycemic Control and Reaping CV-CKD Benefits in T2DM (EVERGREEN) Practice Perspective Dr. Kamal Kant Kohli21 Nov 2023 12:14 PM ISTType 2 diabetes mellitus (T2DM) is growing alarmingly due to rapid urbanization, migration, aging population, and lifestyle changes; with Asia being...
Indian Review Revisits Legacy Effect of Gliclazide in Diabetes Management Dr. Kamal Kant Kohli21 Sept 2023 11:15 AM ISTTaking strong note of the effective glycemic control and vascular benefits shown by early intensive treatment with Gliclazide MR (modified release) in...
Linagliptin The Evergreen Gliptin: Indian Position Paper Highlights Wide Clinical Applicabilities of Linagliptin in T2DM Dr. Kamal Kant Kohli14 Sept 2023 11:45 AM ISTA recent position paper from India has reported that Linagliptin is clinically beneficial across a wide range of patients eliminating the need for...
ESC 2023 Reaffirms CV Safety of Sulphonylureas Agents Dr. Prem Aggarwal30 Aug 2023 11:30 AM ISTThe European Society of Cardiology (ESC) has released new guidelines for managing cardiovascular disease among patients with diabetes, simplifying...
ADA Releases Guidelines Update for Screening and Treatment NAFLD in Type 2 Diabetes, Check Out Details Dr. Kamal Kant Kohli28 July 2023 11:32 AM ISTUnderstanding the close interaction between Non-Alcoholic Fatty Liver Disease & Type 2 Diabetes, and continuously evolving evidence, the American...
